XNCR: Xencor, Inc.
Performance
XNCR +177.63%
Watchlist
Select an item
Summary
XNCR at a glance
XNCR returned +177.63% over the past year and -1.34% a year over five years. Its worst drop in that year was -42.61%, smaller than 33% of stocks on Redstone, and its Sharpe ratio of 1.83 beats 97% of stocks on Redstone. It pays no dividends.
Current Drawdown
0.00%
Rolling Volatility
85.97%
Actions
Metrics
Risk Indicators
Alpha108.07%
Beta1.22x
Sharpe1.83
Sortino3.15
Omega1.37
Calmar4.17
Martin5.09
Profile
About XNCR
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates.
- Sector
- Health Care
- Industry
- Pharmaceutical Preparations
- Market cap
- $2.9B
- Listed
- Dec 2013
- Employees
- 260
- Headquarters
- Pasadena, CA
- Website
- xencor.com
Comparisons